Impact News +++ Anglo American to Exit Platinum Spinoff Valterra with Stake Sale (Bloomberg) +++ VALTERRA Aktie -4,98%

AUTOLUS Aktie

>AUTOLUS Aktienkurs

1.27 EUR +5.8% (Tradegate)

Ask: 1.25 EUR / 8000 Stück

Bid: 1.23 EUR / 8200 Stück

Tagesumsatz: 6900 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AUTOLUS Aktie über LYNX handeln

Intraday

1 Jahr

>AUTOLUS Performance

1 Woche: -6,8%

1 Monat: -38,2%

3 Monate: -24,5%

6 Monate: -26,6%

1 Jahr: -65,4%

laufendes Jahr: -45,6%

>AUTOLUS Aktie

Name:

AUTOLUS THERAP. SP.ADR/1

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US05280R1005 / A2JNZJ

Symbol/ Ticker:

6A3A (Frankfurt) / AUTL (NASDAQ)

Kürzel:

FRA:6A3A, ETR:6A3A, 6A3A:GR, NASDAQ:AUTL

Index:

Webseite:

https://www.autolus.com/

Profil:

Autolus Therapeutics Plc ADR represents shares in ..
>Volltext..

Marktkapitalisierung:

343.19 Mio. EUR

Unternehmenswert:

222.31 Mio. EUR

Umsatz:

25.95 Mio. EUR

EBITDA:

-224.65 Mio. EUR

Nettogewinn:

-196.08 Mio. EUR

Gewinn je Aktie:

-0.74 EUR

Schulden:

270.94 Mio. EUR

Liquide Mittel:

107.75 Mio. EUR

Operativer Cashflow:

-227.21 Mio. EUR

Bargeldquote:

6.69

Umsatzwachstum:

187.52%

Gewinnwachstum:

2.52%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AUTOLUS

Letzte Datenerhebung:

03.09.25

>AUTOLUS Kennzahlen

Aktien/ Unternehmen:

Aktien: 266.14 Mio. St.

Frei handelbar: 90.3%

Leerverk. Aktien: 5.6%

Rückkaufquote: -0.05%

Mitarbeiter: 647

Umsatz/Mitarb.: 0.01 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 530.67%

Bewertung:

KGV: -

KGV lG: -

KUV: 13.84

KBV: 1.54

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -107.53%

Gewinnmarge: -755.73%

Operative Marge: -894.57%

Managementeffizenz:

Gesamtkaprendite: -28.97%

Eigenkaprendite: -52.18%

>AUTOLUS Peer Group

Es sind 601 Aktien bekannt.

>AUTOLUS Chart & Kurs - NASDAQ

>AUTOLUS News

12.08.25 - 22:42	Autolus targets 60+ authorized centers by year-end 2025 while signaling expanded U.S. AUCATZYL access (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:06	Autolus Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $20.9M beats by $7.98M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:03	Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire EN)
	Autolus announced its operational and financial results for the second quarter ended June 30, 2025....

11.08.25 - 17:24	Autolus Therapeutics Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.07.25 - 19:06	Unlocking Oncology′s Future: 3 Trending Cancer Biotech Stocks with ′Strong Buy′ Ratings (Barchart)
	Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts......

24.07.25 - 13:33	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 (GlobeNewswire EN)
	Autolus will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025....

21.07.25 - 13:03	Autolus Therapeutics′ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (GlobeNewswire EN)
	Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization...

15.07.25 - 22:09

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company's 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4)....

13.06.25 - 03:21	What 4 Analyst Ratings Have To Say About Autolus Therapeutics (Benzinga)
	Latest Ratings for AUTL DateFirmActionFromTo May 2021NeedhamMaintainsBuy Mar 2021Redburn PartnersDowngradesBuyNeutral Jan 2021JP MorganDowngradesOverweightNeutral View More Analyst Ratings for AUTL View the Latest Analyst Ratings read more...

12.06.25 - 08:03	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel′s Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire EN)
	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 E...

23.05.25 - 16:48	Autolus Therapeutics gets EU endorsement for leukemia treatment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.05.25 - 14:33	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (GlobeNewswire EN)
	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-ALL...

14.05.25 - 15:33	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire EN)
	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress...

07.05.25 - 18:39	Autolus Therapeutics Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.04.25 - 18:09	Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) (GlobeNewswire EN)
	Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory...

22.04.25 - 13:03	Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 (GlobeNewswire EN)
	Autolus will report Q1 2025 financial results on May 8, 2025....

02.04.25 - 13:03	Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire EN)
	Autolus will present in a fireside chat at the Needham Healthcare Conference on Wednesday, April 9, 2025....

01.04.25 - 13:03	Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025 (GlobeNewswire EN)
	Autolus will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT....

20.03.25 - 17:00	Autolus plans expansion of AUCATZYL centers in 2025 to cover 90% of U.S. patients (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.03.25 - 12:12	Autolus Therapeutics GAAP EPS of -$0.86 beats by $0.03, revenue of $10.12M misses by $7.21M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine Pfarrgemeinde ist ein Verein von Einzelpersonen, bei denen der Hirte am einsamsten ist. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram